Abstract
Chronic oral administration of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil suppressed thymidylate synthetase (TS) gene expression followed by reduction of TS activity in rat mammary tumors induced with 7,12-dimethylbenz[a]anthracene. Addition of medroxyprogesterone acetate (MPA) to the anticancer drug caused an additional decrease in TS and thymidine kinase activities in the tumor growth and restoration of bone loss. These results suggest that the simultaneous administration of MPA and anticancer drugs causes increased inhibition of mammary tumor growth and also diminishes the bone loss.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
9,10-Dimethyl-1,2-benzanthracene
-
Animals
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bone Density / drug effects
-
Estradiol / blood
-
Female
-
Mammary Neoplasms, Experimental / chemically induced
-
Mammary Neoplasms, Experimental / drug therapy*
-
Mammary Neoplasms, Experimental / enzymology
-
Mammary Neoplasms, Experimental / pathology
-
Medroxyprogesterone Acetate / administration & dosage
-
Medroxyprogesterone Acetate / therapeutic use*
-
Organ Size / drug effects
-
Polymerase Chain Reaction
-
Progesterone / blood
-
RNA, Messenger / biosynthesis
-
Rats
-
Rats, Sprague-Dawley
-
Tegafur / administration & dosage
-
Tegafur / therapeutic use*
-
Thymidine Kinase / biosynthesis
-
Thymidylate Synthase / biosynthesis
-
Transcription, Genetic / drug effects
Substances
-
RNA, Messenger
-
Tegafur
-
Progesterone
-
Estradiol
-
9,10-Dimethyl-1,2-benzanthracene
-
Medroxyprogesterone Acetate
-
Thymidylate Synthase
-
Thymidine Kinase